The amino-terminal domain of the androgen receptor co-opts extracellular signal-regulated kinase (ERK) docking sites in ELK1 protein to induce sustained gene activation that supports prostate cancer cell growth

Rosati, Rayna, Patki, Mugdha, Chari, Venkatesh, Dakshnamurthy, Selvakumar, McFall, Thomas, Saxton, Janice, Kidder, Benjamin L., Shaw, Peter E. and Ratnam, Manohar (2016) The amino-terminal domain of the androgen receptor co-opts extracellular signal-regulated kinase (ERK) docking sites in ELK1 protein to induce sustained gene activation that supports prostate cancer cell growth. Journal of Biological Chemistry, 291 (50). pp. 25983-25998. ISSN 1083-351X

Full text not available from this repository.

Abstract

The ETS domain transcription factor ELK1 is in a repressive association with growth genes and is transiently activated through phosphorylation by ERK1/2. In prostate cancer (PCa) cells the androgen receptor (AR) is recruited by ELK1, via its amino-terminal domain (A/B), as a transcriptional co-activator, without ELK1 hyper-phosphorylation. Here we elucidate the structural basis of the interaction of AR with ELK1. The ELK1 polypeptide motifs required for co-activation by AR versus those required for activation of ELK1 by ERK were systematically mapped using a mammalian two-hybrid system and confirmed using a co-immunoprecipitation assay. The mapping precisely identified the two ERK-docking sites in ELK1, the D-box and the DEF (docking site for ERK, FXFP) motif, as the essential motifs for its cooperation with AR(A/B) or WTAR. In contrast, the transactivation domain in ELK1 was only required for activation by ERK. ELK1-mediated transcriptional activity of AR(A/B) was optimal in the absence of ELK1 binding partners, ERK1/2 and serum-response factor. Purified ELK1 and AR bound with a dissociation constant of 1.9 × 10−8 m. A purified mutant ELK1 in which the D-box and DEF motifs were disrupted did not bind AR. An ELK1 mutant with deletion of the D-box region had a dominant-negative effect on androgen-dependent growth of PCa cells that were insensitive to MEK inhibition. This novel mechanism in which a nuclear receptor impinges on a signaling pathway by co-opting protein kinase docking sites to constitutively activate growth genes could enable rational design of a new class of targeted drug interventions.

Item Type: Article
RIS ID: https://nottingham-repository.worktribe.com/output/835886
Keywords: Androgen receptor, ETS transcription factor family, Extracellular signal-regulated kinase (ERK), Prostate cancer, Transcription
Schools/Departments: University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Life Sciences
Identification Number: https://doi.org/10.1074/jbc.M116.745596
Depositing User: Eprints, Support
Date Deposited: 08 Mar 2017 13:54
Last Modified: 04 May 2020 18:26
URI: https://eprints.nottingham.ac.uk/id/eprint/41159

Actions (Archive Staff Only)

Edit View Edit View